FDA warns Dollar Tree regarding the sale of imported adulterated drugs
Category: #health  By Mateen Dalal  Date: 2019-11-16
  • share
  • Twitter
  • Facebook
  • LinkedIn

FDA warns Dollar Tree regarding the sale of imported adulterated drugs
  • FDA’s new warning letter is asking Dollar Tree to ensure the company does not import adulterated medicines
     
  • Manufacturers mentioned in the letter include Hangzhou Zhongbo and Shanghai Weierya Daily Chemicals

Reports confirm that the U.S. Food and Drug Administration recently sent a warning letter to Virginia-based Greenbrier International, trading as Dollar Tree, about receiving OTC drugs made by foreign companies which have been discovered as being adulterated. These include Assured branded drugs as well as acne treatment pads.

Apparently, the manufacturers and suppliers in concerns have already received separate warning letters from the FDA last year, besides being placed on import alert. The letter enumerated several manufacturing practice violations at the facilities of these manufacturers, who produce the Assured brand OTC drugs of Dollar Tree and other products sold by the company and its outlets.

FDA’s new warning letter is asking Dollar Tree to adopt systems for ensuring the company does not import adulterated medicines. Responding to the letter, Dollar Tree has confirmed it is co-operating with the U.S. FDA and has plans for meeting with the federal agency.

Dollar Tree’s vice president for investor relations, Randy Guiler said the company is committed towards the safety of its customers and has implemented strong, rigorous testing programs to ensure the products from its third-party manufacturers are safe.

According to the warning letter, Dollar Tree has 15 working days for responding to the FDA in writing, whereas any failure to correct the violations quickly may lead to legal actions, without further notice. The FDA has requested consumers as well as healthcare professionals to report any adverse events resulting from the use of these OTC drugs produced by the contract manufacturers.

Some of the manufacturers mentioned in the letter include Hangzhou Zhongbo Industrial Company Ltd and Shanghai Weierya Daily Chemicals Factory. It has been indicated that these companies do not meet the requirements to test raw materials and drugs for pathogens and quality.

Director of the Office of Compliance at the Center for Drug Evaluation and Research, FDA, Donald D. Ashley commented that Americans deserve medicines which are safe, effective and comply with the agency's quality standards. Importing and distributing products from manufacturers that are in violation of the federal law is unacceptable, he sternly mentioned.

 

Source Credits: https://edition.cnn.com/2019/11/14/health/fda-dollar-tree-warning-bn/index.html

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More

More News By Mateen Dalal

Wipro recognized as global leader in Software Defined Network Systems
Wipro recognized as global leader in Software Defined Network Systems
By Mateen Dalal

Wipro has established a strong name as a key WAN services provider. Rising star in SD Network Security Services and SDN Transformation Services, claims report. The network delivery is managed through a wide variety of products, processes, and too...

Microsoft to fix an active security flaw in Internet Explorer
Microsoft to fix an active security flaw in Internet Explorer
By Mateen Dalal

Microsoft, the renowned American tech giant, reportedly verified the presence of a security flaw that is affecting Internet Explorer (IE) and is being used by hackers. The company also said it is working to find a fix for this bug, which would be rel...

Dermtech signs a commercial & medicare advantage coverage agreement
Dermtech signs a commercial & medicare advantage coverage agreement
By Mateen Dalal

DermTech Inc., a San Diego based biotechnology company that is involved in precision dermatology, has recently announced signing a contract with a regional health plan to develop its gene expression based PLA (Pigmented Lesion Assay) for prior detect...